Therapeutic effect of etoposide on experimental psoriasis

Chinese Journal of Pharmacology and Toxicology

Volumn 22, Issue 6, 2008, Pages 440-445

  Xie, Qing ^a   Wang, Jin ^b   Wang, Ju Ying ^b   Yan, Hui Lan ^a   Li, Ying Quan ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Etoposide; Interleukin 10; Interleukin 2; Mitotic index; Psoriasis; Tumor necrosis factor

Indexed keywords

ETOPOSIDE; INTERLEUKIN 10; INTERLEUKIN 2; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG MECHANISM; ESTRUS CYCLE; FEMALE; MITOSIS INDEX; MOUSE; NONHUMAN; PSORIASIS; RADIOIMMUNOASSAY; VAGINA EPITHELIUM;

MUS;

EID: 58149218513     PISSN: 10003002     EISSN: None     Source Type: Journal    
DOI: 10.3867/j.issn.1000-3002.2008.06.008     Document Type: Article

References (15)

1. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor[J]. Eur J Cancer, 1998, 34(10):1514-1521.
2. Liu JH, Tang HL, Ruan WY. Etoposide induces apoptosis via mitochondrial signaling pathway with cytochrome c release in Jurkat leukemia cells[J]. Chin J Pathophysiol, 2007, 23(3):453-459.
3. Jarrett A. The physiology and pathophysiology of the skin[J]. Lancet, 1973, 2(7826):445.
4. Van Scott EJ, Bonder RH. Intravaginal and intrarectal screening of antimitotic drugs for topical effectiveness [J]. J Invest Dermatol, 1971, 56(2):132-139.
5. Lin X, Wilkinson DI, Huang T, Farber EM. Experimental studies on topoisomerase inhibitor camptothecin as an antipsoriatic agent[J]. Chin Med J(Engl), 1999, 112(6):504-508.
6. Liu XM, Qi X, Song ZQ, Cui CH, Lin XR. Clinical and experimental observation on treatment of psoriasis with Radix Astragali injection[J]. Chin J Dermatol, 2001, 34(2) : 113-114.
7. McKay IA, Leigh IM. Altered keratinocyte growth and differentiation in psoriasis[J]. Clin Dermatol, 1995, 13(2):105-114.
8. Kastelan M, Massari LP, Pasic A, Gruber F. New trends in the immunopathogenesis of psoriasis[J]. Acta Dermatovenerol Croat, 2004, 12(1):26-29.
9. Philipp S, Wolk K, Kreutzer S, Wallace E, Ludwig N, Roewert J, et al. The evaluation of psoriasis therapy with biologies leads to a revision of the current view of the pathogenesis of this disorder[J]. Expert Opin Ther Targets, 2006, 10(6):817-831.
10. Martin A, Gutierrez E, Muglia J, McDonald CJ, Guzzo C, Gottlieb A, et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis[J]. J Am Acad Dermatol, 2001, 45(6):871-881.
11. Yang HP, Zhou WQ, Sang HG, Sun JF, Ye YY. Effect of methotrexate on IL-10 and IFN-γ production by peripheral white blood cells in patients with psoriasis[J]. China J Lepr Skin Dis, 2000, 16(3):141-143.
12. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients [J]. J Invest Dermatol, 1999, 113(5):752-759.
13. Girolomoni G, Abeni D. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis[J]. Arch Dermatol, 2001, 137(6):784-785.
14. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study[J]. J Am Acad Dermatol, 2006, 55(4):598-606.
15. Strober BE. The treatment of psoriasis with etanercept [J]. Semin Cutan Med Surg, 2005, 24(1):28-36.